PharmaCyte Biotech, Inc.
PMCB- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001157075
No open-market purchases or sales by PharmaCyte Biotech, Inc. insiders were filed in the last 90 days; 32 institutions reported holding it in 13F filings for Q2 2026, worth $586.2K in total; no superinvestor holds it.
Q1 2025 vs. Q4 2024
How the institutions holding PharmaCyte Biotech, Inc. changed between Q4 2024 and Q1 2025.
All holders in Q1 2025All holders in Q4 2024
| Measure | Q4 2024 | Q1 2025 | Change |
|---|---|---|---|
| Holders | 23 | 26 | +3 |
| Shares | 600.8K | 568.2K | −32.6K (−5.4%) |
| Value | $934.3K | $709.9K | −$224.4K (−24.0%) |
New holders (4)
Institutions that held PharmaCyte Biotech, Inc. at the end of Q1 2025 but not at the end of Q4 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| National Bank of Canada | 3,300 | $4.09K | 0.00% |
| BlackRock, Inc. | 14 | $18 | 0.00% |
| FMR LLC | 6 | $8 | 0.00% |
| IFP Advisors, Inc | 1 | $1 | 0.00% |
Sold out (1)
Institutions that held PharmaCyte Biotech, Inc. at the end of Q4 2024 and filed for Q1 2025 without it.
| Institution | Shares, Q4 2024 | Value, Q4 2024 |
|---|---|---|
| Royal Bank of Canada | 98 | $0 |